Sildenafil: Clinical Overview
Indications and Mechanism
Sildenafil is a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction and pulmonary arterial hypertension (PAH), working by preventing cyclic GMP degradation in vascular smooth muscle, leading to vasodilation. 1, 2
- PDE5 is strongly expressed in lung tissue and is upregulated in chronic pulmonary hypertension, making sildenafil particularly effective for PAH 1
- The drug augments endogenous nitric oxide effects, reducing pulmonary arterial pressure and pulmonary vascular resistance 3
Recommended Dosing
For Pulmonary Arterial Hypertension
The FDA-approved dose is 20 mg orally three times daily (TID), administered 4-6 hours apart. 2
- Clinical trials showed similar improvements in 6-minute walk distance with 20 mg, 40 mg, and 80 mg TID (45 m, 46 m, and 50 m respectively), but the FDA approved only the 20 mg dose 1, 4
- However, for inadequate responders, expert consensus supports titrating up to 80 mg TID, particularly when added to background IV epoprostenol therapy 4
- When combining with IV epoprostenol, start at 20 mg every 8 hours and titrate to 80 mg every 8 hours over 8 weeks 4
- Long-term data (1 year) demonstrate sustained improvement of 51 meters in 6-minute walk distance at 80 mg TID 1, 4
For Erectile Dysfunction
- Standard dosing for erectile dysfunction follows different protocols than PAH treatment 5
Absolute Contraindications
Never combine sildenafil with nitrate medications—this causes synergistic vasodilation leading to potentially life-threatening hypotension. 6, 2
- Avoid nitrates for at least 24 hours after sildenafil use 6
- Absolute contraindication with riociguat due to hypotension risk 4
- Do not use in patients with resting hypotension (BP <90/50 mmHg) 6
- Avoid in severe left ventricular outflow obstruction 6
- Contraindicated in autonomic dysfunction 6
- Control uncontrolled hypertension (BP ≥180/110 mmHg) before prescribing 6
Common Adverse Effects
Headache is the most common adverse effect (16% of patients), directly related to the drug's vasodilatory mechanism causing cerebral vessel dilation. 4, 6
- Flushing or facial redness/warmth occurs in 10% of patients 4, 6
- Dyspepsia (upset stomach/epigastric discomfort) is common 4, 2
- Nasal congestion and epistaxis (nosebleeds) are frequent vasodilatory effects 4, 2
- Rhinitis is commonly reported 4
- Most adverse effects are transient, mild to moderate in severity, with only 3% discontinuation rate in clinical trials 4
Serious Adverse Effects
Priapism (erections lasting >4 hours) requires immediate medical attention—instruct patients to seek emergency care if this occurs. 4, 2
- Very-low-quality evidence suggests PDE-5 inhibitors may be associated with increased risk for "possible NAION" (nonarteritic anterior ischemic optic neuropathy), though not confirmed NAION 4
- Sudden decrease or loss of vision in one or both eyes—advise patients to contact physician immediately 2
- Sudden decrease or loss of hearing—requires immediate medical evaluation 2
- Heart attack, stroke, irregular heartbeats, and death have occurred, mostly in men with pre-existing cardiac disease 2
- Low blood pressure may cause faintness or dizziness—patients should lie down if symptomatic 2
- Increased shortness of breath beyond baseline may indicate worsening underlying condition 2
Drug Interactions and Precautions
Sildenafil can be safely prescribed with most antihypertensive agents including diuretics and ARBs without significant adverse reactions. 6
- Ritonavir and other HIV protease inhibitors require dose adjustment 2
- Ketoconazole and itraconazole may increase sildenafil levels 2
- Bosentan decreases sildenafil plasma levels when used in combination 7
- Mild to moderate renal or hepatic failure does not significantly affect metabolism 7
Combination Therapy Strategies
For patients with inadequate response to sildenafil monotherapy, consider adding inhaled treprostinil (titrated to 54 μg four times daily), which improves exercise capacity by 20 meters at 12 weeks. 4
- Patients with baseline 6-minute walk distance <300 meters are more likely to benefit from adding inhaled treprostinil 4
- When adding sildenafil to stable IV epoprostenol, patients with baseline 6-minute walk distance >325 meters show greater benefit 4
- Sildenafil combined with inhaled NO achieves greater PVR reduction than either agent alone 1
- Aerosolized iloprost causes more marked mPAP and PVR reduction than sildenafil alone, but combination therapy provides greater and more prolonged effects 1
- Adding bosentan to sildenafil lacks sufficient evidence for routine recommendation 4
Clinical Efficacy in PAH
Sildenafil significantly improves exercise capacity, WHO functional class, and cardiopulmonary hemodynamics in patients with idiopathic PAH or PAH associated with connective tissue disease. 1, 4
- Reduces mean pulmonary arterial pressure and pulmonary vascular resistance 1
- Increases cardiac index 1
- Improves 6-minute walk distance by 45-50 meters compared to placebo (p<0.001) 1, 4
- Effectiveness demonstrated primarily in NYHA functional class II-III patients 4
- Sildenafil can be considered for PAH associated with systemic sclerosis when bosentan is ineffective or contraindicated 4
Critical Pitfalls to Avoid
Do not assume the FDA-approved 20 mg TID dose is optimal for all patients—clinical trials and expert consensus support titration up to 80 mg TID for inadequate responders. 4
- Do not add a second PAH-specific drug without first ensuring adequate trial of initial monotherapy at optimal doses 4
- When combined with IV epoprostenol, sildenafil causes more headaches and dyspepsia—counsel patients accordingly 4
- Do not use tadalafil on background bosentan therapy, as data do not support additional benefit of this specific combination 4
- Male patients treated with riociguat must avoid PDE-5 inhibitors for erectile dysfunction 4
Alternative PDE5 Inhibitors
Tadalafil 40 mg daily provides clinical benefit as monotherapy in PAH, with the lowest incidence of flushing among PDE5 inhibitors. 4, 8